Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
Sponsor: ModernaTX, Inc.
Summary
This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
Official title: A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
350
Start Date
2026-04-29
Completion Date
2028-11-09
Last Updated
2026-05-28
Healthy Volunteers
Yes
Conditions
Interventions
mRNA-1982
Suspension for injection
Placebo
Suspension for injection
Locations (8)
Colchester Research Group
Truro, Nova Scotia, Canada
Bluewater Clinical Research Group Inc.
Sarnia, Ontario, Canada
Stouffville Medical Research Institute Inc.
Stouffville, Ontario, Canada
Dr. Anil K. Gupta Medicine Professional Corporation Inc.
Toronto, Ontario, Canada
Diex Recherche Inc. - Division Joliette
Joliette, Quebec, Canada
Diex Recherche Inc. - Division Sherbrooke
Sherbrooke, Quebec, Canada
Diex Recherche Inc. - Division Victoriaville
Victoriaville, Quebec, Canada
Diex Recherche Inc. - Division Quebec
Québec, Canada